Screening of Autoantibodies in Type 1 Diabetes

What Are the Different Autoantibodies Present in Type 1 Diabetes?

Have you heard about autoantibody screening? It is a crucial step that helps identify if you or a loved one is at risk of type 1 diabetes. It aids in early intervention and in selecting the most effective treatment path.

Think of autoantibodies as your body's security system gone rogue. Instead of attacking foreign invaders (like viruses), they mistakenly target and attack the body’s own healthy cells and tissues.

There are many forms of autoantibodies related to type 1 diabetes, such as

1. Islet cell autoantibodies: These are the earliest autoantibodies detected in type 1 diabetes, serving as a marker of autoimmune destruction of pancreatic beta cells.

2. Insulin autoantibodies: These attack the insulin naturally produced by your body. These are often the first antibodies detected in patients with recently developed T1D.

3. Glutamic acid decarboxylase autoantibodies: They act against glutamic acid decarboxylase, an enzyme that synthesises gamma-aminobutyric acid. It is present in up to 80 percent of patients with T1D. This is commonly checked using the GAD antibody test for diabetes.

4. Insulinoma-associated antigen-2 autoantibodies (IA-2A): These target a specific protein found on the surface of your insulin-producing pancreatic cells. These antibodies are present in approximately 60 percent of individuals with type 1 diabetes.

What Are the Benefits of Autoantibody Screening in Type 1 Diabetes?

The following are the benefits of autoantibody screening in type 1 diabetes:

1. Diagnosis: The presence of autoantibodies is an essential hallmark of the T1D condition. The screening for the presence of these autoantibodies can aid in diagnosis. Autoantibodies play a crucial role in diagnosis, especially when symptoms are unclear or a person exhibits no apparent symptoms. Identifying these antibodies helps confirm whether it is type 1 diabetes (T1D) or another form of diabetes.

2. Prognosis: The specific type and level of autoantibodies detected can provide valuable insights into your prognosis. They indicate your risk of developing T1D, and also how quickly the condition might progress. Multiple antibodies indicate a greater risk of T1D, while the absence of antibodies shows a lower risk.

3. Prediction: Autoantibodies help predict the likelihood of TID onset in individuals at a higher risk. High-risk people are those with a genetic or family history. Screening for these autoantibodies can help identify individuals at risk and aid in early detection or prevention.

4. Treatment guidance: Autoantibodies can also aid in the design of a personalised treatment plan.

5. Research: Autoantibodies play a crucial role in T1D research, as they offer valuable insights into the underlying immune mechanisms. Staging through studies related to autoantibody prevalence and kinetics determines at which stages T1D develops.

6. Preventing complications: Screening tests for T1D autoantibodies can lead to positive clinical outcomes. This includes reduced diabetic ketoacidosis, improved blood sugar management, and beneficial effects on all T1D complications.

What Are the Screening Tests Available for Detecting Autoantibodies in Type 1 Diabetes?

Screening tests are crucial for the diagnosis of type 1 diabetes. They help doctors detect or rule out the presence of other autoantibodies and potential conditions. For those who are uncertain about their risk, it provides clarity and lessens anxiety. These are some of the screening tests done to see the presence of autoantibodies of T1D:

1. Islet cell autoantibodies assay (ICA): This test rules out the presence of antibodies that target islet cells in the pancreas. These cells produce hormones, such as insulin, and their destruction is a hallmark of TID. Islet cell autoantibody is the first autoantibody detected in type 1 diabetes. Its detection is associated with the development of clinical symptoms.

2. Insulin autoantibodies assay (IAA): This test rules out the presence of antibodies that target endogenous insulin. The insulin autoantibody assay is the most common test used to detect antibodies in T1D. The presence of this antibody indicates the destruction of pancreatic beta cells.

3. Glutamic acid decarboxylase autoantibodies (GADA) assay: This test is performed to detect the presence of antibodies that target glutamic acid decarboxylase, an enzyme involved in the synthesis of gamma-aminobutyric acid. This antibody is seen in almost 80 percent of patients with T1D. The detection of these antibodies is also associated with the development of clinical symptoms.

4. Insulinoma-associated antigen-2 autoantibodies (IA-2A) assay: This test rules out the presence of antibodies that target IA-2A, a transmembrane protein seen in pancreatic beta cells. These antibodies are typically found in approximately 60 percent of people with T1D. These antibodies can be detected by the destruction of beta cells and the development of clinical symptoms.

5. Zinc transporter 8 autoantibodies (ZnT8A) assay: This test rules out the presence of antibodies that target ZnT8A, a protein responsible for insulin secretion. These antibodies are seen in about 70 percent of people with T1D.

What Are the Limitations of Autoantibody Screening in Type 1 Diabetes?

It is common for test results to fluctuate. It can be confusing or even alarming. Do not worry if your doctor orders repeat testing. It prevents misunderstandings and provides a clear picture of your health. The following are some of the limitations of autoantibody screening in T1D:

1. False positive results: Autoantibody screening may yield false positive results. This means that the presence of autoantibodies is observed in individuals who do not have T1D. This may be caused by cross-reactivity with other autoantibodies or non-specific binding.

2. False-negative results: Sometimes, a test may yield a false-negative result. This indicates the absence of antibodies even when T1D is present. This might occur in the early stages. Your body may not have produced enough antibodies to detect them accurately.

3. Variability in autoantibody levels: Autoantibody levels can vary. This makes it hard to interpret a single screening test. You may need several tests to confirm if antibodies are present or not.

4. Islet autoantibodies: These can also be seen in other autoimmune endocrine conditions, such as Hashimoto's thyroiditis (occurs when the immune system attacks the thyroid gland) or autoimmune Addison's disease (when the adrenal gland does not produce enough hormone). These tests are conducted only in non-diabetic individuals for research purposes.

Does the Type 1 Autoantibody Test Have Any Risk Factors?

Like any blood test, there are minor risks, such as light bruising or feeling slightly lightheaded. However, these side effects usually subside within minutes. When the needle is used, the person may feel a slight prick, sting, or pain in the hand. However, typically it subsides within a few minutes. If a person takes insulin before screening, it can affect the test results. A person does not need to prepare for the test; however, the doctor must be aware of all the patient's medications.

Conclusion

Screening for autoantibodies in T1D may be helpful for patients who are at high risk of developing diabetes. Children and adults typically have different autoantibody profiles. When young children are at risk for diabetes, IAA is normally the first marker to show up. Diabetes-related autoantibody testing is primarily recommended to differentiate type 1 diabetes from diabetes due to other causes. This test enables the early detection and treatment of diabetes as soon as symptoms appear. It lessens the likelihood of associated complications and helps establish better diabetic control. For more information, please consult our specialist at iCliniq.

Key Takeaways

• Autoantibody screening is helpful for patients who are at high risk of developing diabetes.

• Diabetes-related autoantibody testing is primarily ordered to help differentiate between type 1 diabetes and diabetes due to other causes.

• When the immune system destroys 80 to 90 percent of the beta cells, symptoms of diabetes, such as excessive thirst, frequent urination, weight loss, and poor wound healing, become apparent.

• A diabetic medical crisis may develop over a few weeks or even a few days if the symptoms are not identified and hyperglycemia is not treated.